Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Castrate-sensitive”

18 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 18 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04748042
What this trial is testing

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Who this might be right for
Prostate CancerCastrate Sensitive Prostate CancerOligometastatic Disease
University of Michigan Rogel Cancer Center 21
Not applicableStudy completedNCT02376296
What this trial is testing

Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients

Who this might be right for
Prostate Cancer
Saladax Biomedical, Inc. 35
Large-scale testing (Phase 3)Active Not RecruitingNCT05884398
What this trial is testing

An Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

Who this might be right for
Metastatic Castrate-sensitive Prostate Cancer
Janssen Research & Development, LLC 420
Testing effectiveness (Phase 2)Study completedNCT03899467
What this trial is testing

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Suzhou Kintor Pharmaceutical Inc, 61
Early research (Phase 1)Active Not RecruitingNCT06555796
What this trial is testing

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

Who this might be right for
Prostate CancerHigh-risk Biochemical RecurrenceHigh Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer+1 more
Amgen 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT05067140
What this trial is testing

ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
Novartis Pharmaceuticals 164
Testing effectiveness (Phase 2)Looking for participantsNCT06654336
What this trial is testing

Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

Who this might be right for
Prostate AdenocarcinomaCastration Sensitive Prostate Cancer
Ontario Clinical Oncology Group (OCOG) 162
Not applicableLooking for participantsNCT06429813
What this trial is testing

Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)

Who this might be right for
Castrate Sensitive Prostate CancerMetastatic Prostate Cancer
Paul Viscuse 24
Testing effectiveness (Phase 2)Looking for participantsNCT05422911
What this trial is testing

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

Who this might be right for
Metastatic CancerNeoplasm, ProstateCastrate-sensitive+1 more
Sun Pharmaceutical Industries Limited 192
Early research (Phase 1)Looking for participantsNCT04729114
What this trial is testing

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration Resistant Prostate CancerMetastatic Castration-sensitive Prostate Cancer
Astellas Pharma Global Development, Inc. 174
Testing effectiveness (Phase 2)Study completedNCT04335682
What this trial is testing

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Who this might be right for
Metastatic Prostate CancerProstate Cancer MetastaticProstate Cancer+3 more
Alliance Foundation Trials, LLC. 111
Testing effectiveness (Phase 2)Looking for participantsNCT06800313
What this trial is testing

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
Janssen Research & Development, LLC 190
Not applicableActive Not RecruitingNCT02730338
What this trial is testing

INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)

Who this might be right for
Metastatic Prostate Cancer
Movember Foundation 866
Large-scale testing (Phase 3)Looking for participantsNCT06931340
What this trial is testing

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Who this might be right for
Castration-Sensitive Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Alliance for Clinical Trials in Oncology 1,260
Testing effectiveness (Phase 2)Study completedNCT03860987
What this trial is testing

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Who this might be right for
Castrate Sensitive Prostate Cancer
National Cancer Institute (NCI) 12
Large-scale testing (Phase 3)Looking for participantsNCT07028853
What this trial is testing

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Who this might be right for
Metastatic Castration Sensitive Prostate Cancer (mCSPC)Hormone Sensitive Prostate CancerProstate Cancer+1 more
Pfizer 1,000
Testing effectiveness (Phase 2)Ended earlyNCT01377389
What this trial is testing

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center 30
Not applicableLooking for participantsNCT06652607
What this trial is testing

PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer

Who this might be right for
Prostate CancerMetastatic CancerCastrate Sensitive Prostate Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 152